NDRI’s Board of Directors met on Friday, November 2, 2018 to review and approve the 2017 audited financial statements, filing of Form 990, year-to-date financial and programmatic performance and NDRI’s 2019 Budget. Our executive staff provided the Board with a detailed overview of our many successful projects and partnerships, and included an update on the current status of NIH appropriations.
We are excited to announce the election of David M. Albert, JD, to the NDRI Board of Directors. David is the Director of Strategy, Emerging Business and Venture Capital group, Cozen O’Connor.
We were honored to have our special guest Dr. Kristin Ardlie, Director, Biological Samples at The Board Institute of Harvard, MIT join our meeting for an insightful presentation of The Broad’s Single Cell Analysis Project.
Thank you to all who participated in the meeting and to our financial auditing partners from EisnerAmper for hosting a productive meeting of NDRI’s Board of Directors with a wonderful view from One Logan Square of the Benjamin Franklin Parkway in Philadelphia.